{"eventGroups":[{"description":"Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nperipheral blood stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies","id":"EG000","otherNumAffected":15,"otherNumAtRisk":63,"seriousNumAffected":5,"seriousNumAtRisk":63,"title":"Treatment (Rituximab Pre- and Post-transplant)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63,"numEvents":3}],"term":"ARDS"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":63,"numEvents":3}],"term":"Diffuse Alveolar Hemorrhage"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":63,"numEvents":12}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63,"numEvents":4}],"term":"Elevated Bilirubin"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63,"numEvents":5}],"term":"Elevated Creatinine"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63,"numEvents":1}],"term":"Multiple Pulmonary Emboli"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63,"numEvents":1}],"term":"Suspected Pulmonary Embolism"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":63,"numEvents":2}],"term":"Death Due to Infection"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63,"numEvents":1}],"term":"Sepsis and Tachycardia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63,"numEvents":1}],"term":"Sepsis, Respiratory Failure, Mental Status Change"}],"timeFrame":"AEs: Conditioning through Day 100; SAEs: Conditioning through Day 200"}